ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Avapritinib

Also written as “avapritinib” and “CS3007 (BLU-285)”.

Its studies are mostly in Gastrointestinal Stromal Tumors · Mastocytosis, Systemic · Leukemia, Mast-Cell · Central Nervous System Neoplasms, led by 2 companies.

Drug pageAvapritinib: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 29, 202110 company-led studies, 2 open or runningNext primary completion: Jun 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi92 open or runningphase 4since Mar 29, 2021Jul 23, 2015Jun 23, 2027phase 2 · NCT03731260
CStone Pharmaceuticalsits history only10 open or runningphase 2since Dec 9, 2019Dec 9, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2015First study: phase 1 study in Gastrointestinal Stromal TumorsFirst studyNCT02508532 · 250 enrolled · United States, Belgium, France and more
  2. Sep 15, 2015Phase 1 study in Mastocytosis, SystemicNCT02561988 · 86 enrolled · United States, United Kingdom
  3. Jun 9, 2017Named avapritinibINNProposed as its International Nonproprietary Name in WHO's List 117
  4. Mar 7, 2018Phase 3 study in Gastrointestinal Stromal TumorsNCT03465722 · 476 enrolled · United States, Australia, Austria and more
  5. May 3, 2018Phase 2 study in Mastocytosis, SystemicNCT03580655 · 107 enrolled · United States, Austria, Canada and more
  6. Oct 30, 2018Phase 2 study in Mastocytosis, SystemicNCT03731260 · 251 enrolled · United States, Belgium, Canada and more
  7. Feb 9, 2021Phase 2 study in Central Nervous System NeoplasmsNCT04773782 · 29 enrolled · United States, Australia, Austria and more
  8. Mar 29, 2021Phase 4 study in Gastrointestinal Stromal TumorsNCT04825574 · 2 enrolled · France
  9. May 27, 2021Phase 1 study in Gastrointestinal Stromal TumorsNCT04908176 · 10 enrolled · United States
  10. Dec 19, 2024Phase 4 study in Mastocytosis, SystemicNCT06748001 · 60 planned · Belgium, Canada, France and more

Ahead

  1. Jun 23, 2027Primary completion: phase 2 study in Mastocytosis, SystemicNCT03731260
  2. Dec 31, 2027Primary completion: phase 4 study in Mastocytosis, SystemicNCT06748001

TargetBeta

KIT →PDGFRA →read by rule
“An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38

Studies

All 9 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06748001Mastocytosis, Systemic · Belgium, Canada, France and more4RecruitingDec 31, 202760
NCT04908176Gastrointestinal Stromal Tumors · United States1CompletedMar 1, 202410
NCT04825574Gastrointestinal Stromal Tumors · France4CompletedNov 23, 20232
NCT04773782Central Nervous System Neoplasms · United States, Australia, Austria and more2CompletedNov 21, 202529
NCT03731260Mastocytosis, Systemic · United States, Belgium, Canada and more2Active, not recruitingJun 23, 2027251
NCT03580655Mastocytosis, Systemic · United States, Austria, Canada and more2CompletedDec 18, 2024107
NCT03465722Gastrointestinal Stromal Tumors · United States, Australia, Austria and more3CompletedMar 9, 2020476
NCT02561988Mastocytosis, Systemic · United States, United Kingdom1CompletedOct 5, 202286
NCT02508532Gastrointestinal Stromal Tumors · United States, Belgium, France and more1CompletedMar 6, 2020250

How it is read

Names in the registry

  • “Avapritinib”, 7 entries
  • “avapritinib”, 2 entries
  • “CS3007 (BLU-285)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.